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Abstract 
In cancer, kinases are often activated and phosphatases suppressed, leading to aberrant activation of 
signaling pathways driving cellular proliferation, survival, and therapeutic resistance. Although pancreatic 
ductal adenocarcinoma (PDA) has historically been refractory to kinase inhibition, therapeutic activation 
of phosphatases is emerging as a promising strategy to restore balance to these hyperactive signaling 
cascades. In this study, we hypothesized that phosphatase activation combined with kinase inhibition 
could deplete oncogenic survival signals to reduce tumor growth. We screened PDA cell lines for kinase 
inhibitors that could synergize with activation of protein phosphatase 2A (PP2A), a tumor suppressor 
phosphatase, and determined that activation of PP2A and inhibition of mTOR synergistically increase 
apoptosis and reduce oncogenic phenotypes in vitro and in vivo. This combination treatment resulted in 
suppression of AKT/mTOR signaling coupled with reduced expression of c-MYC, an oncoprotein 
implicated in tumor progression and therapeutic resistance. Forced expression of c-MYC or loss of PP2A 
B56α, the specific PP2A subunit shown to negatively regulate c-MYC, increased resistance to mTOR 
inhibition. Conversely, decreased c-MYC expression increased the sensitivity of PDA cells to mTOR 
inhibition. Together, these studies demonstrate that combined targeting of PP2A and mTOR suppresses 
proliferative signaling and induces cell death and implicates this combination as a promising therapeutic 
strategy for patients with PDA. 
 
Precis 
Therapeutic activation of the serine/threonine protein phosphatase, PP2A, can function synergistically 
with mTOR inhibition to attenuate oncogenic and survival signaling in pancreatic cancer.   
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Introduction 
 Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States and 
while chemotherapy can provide a survival benefit, the 5-year survival rate for pancreatic ductal 
adenocarcinoma (PDA) patients remains the lowest of all major cancers (1). Although KRAS mutations 
are an almost universal event in PDA, mutant KRAS continues to be a highly undruggable target and 
significantly contributes to therapeutic resistance (2, 3). Consistent with the high prevalence of mutant 
KRAS in PDA, single agent kinase inhibitors have had little clinical success in PDA patients, likely due 
to cellular plasticity and adaptation to alternative oncogenic signaling pathways (4, 5).  
Protein Phosphatase 2A (PP2A) is a serine/threonine phosphatase that regulates multiple 
signaling cascades implicated in cancer progression, including downstream effectors of KRAS (6). 
Inhibition of PP2A contributes to oncogenesis in multiple tumor types, highlighting the importance of this 
protein in maintaining normal kinase activity (7). PDA cells have reduced PP2A activity and an 
upregulation of the PP2A inhibitors, CIP2A and SET (8, 9). Further, high CIP2A expression in PDA 
patients correlates with decreased overall survival (10), suggesting that suppression of PP2A may 
significantly contribute to PDA cell survival. As such, compounds that activate PP2A are emerging as 
promising cancer therapeutics (11). The majority of PP2A activating agents disrupt the interaction 
between PP2A and CIP2A or SET, indirectly increasing PP2A activation and reducing tumor growth (12-
14). However, tricyclic neuroleptics have direct PP2A activating properties and our recent study by 
Sangodkar et. al. demonstrated that derivatives of these compounds, known as small-molecule activators 
of PP2A (SMAPs), specifically bind to the PP2A A subunit and facilitate PP2A activation resulting in 
reduced oncogenic phenotypes both in vitro and in vivo (15, 16). The specificity of these effects was 
demonstrated by loss of the therapeutic efficacy of SMAPs with the expression of the SV40 small T 
antigen, a known PP2A inhibitor, or expression of A subunit mutations. Thus, SMAPs directly bind the 
PP2A A subunit and predominately function through PP2A activation (16). Given the multiple oncogenic 
targets of PP2A, compounds that activate this phosphatase may prevent or suppress cancer cell signaling 
plasticity in response to kinase inhibitors. 
Here we investigate the therapeutic efficacy of combining kinase inhibitors with phosphatase 
activators to synergistically attenuate oncogenic signaling and induce cell death in PDA cells. In order to 
identify kinases susceptible to PP2A activation, we initially assessed cell viability in a 120-kinase 
inhibitor screen in combination with an indirect PP2A activator, OP449. Results of this study led us to 
pursue mTOR inhibitor combinations with OP449 and DT1154, a direct SMAP. The PI3K/AKT/mTOR 
signaling node is activated downstream of KRAS and has been shown to be deregulated in a large percent 
of PDA patients (17-19). Clinically, mTOR inhibitors have shown little success as single agent 
compounds, primarily due to resistance mechanisms, making this node an ideal target for therapeutic 
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combination strategies (20-22). INK128, an ATP-competitive mTORC1/2 inhibitor, was synergistic with 
PP2A activation and in combination with DT1154 resulted in a significant increase in apoptosis and 
reduced tumor growth in vivo over single agent treatment. mTOR inhibition alone suppressed 
AKT/mTOR signaling but was unable to drive a significant loss of the oncoprotein c-MYC (MYC) 
(MYCHigh/mTORLow). In contrast, the synergistic combination of INK128 and DT1154 reduced the 
activation of MYC and AKT/mTOR (MYCLow/mTORLow), identifying MYC signaling as a potential 
resistance mechanism by which pancreatic cancer cells survive mTOR inhibition. Together, these studies 
support the use of PP2A-activating compounds in combination with kinase inhibitors as a novel 
therapeutic strategy in PDA. 
 
Materials and Methods 
Cell culture, Knockdown, Adenoviral Transfection. PANC1, HPAFII, MIAPACA2, ASPC1, PANC89 
and HPNE pancreatic cells lines were obtained from Michel Ouellette (University of Nebraska Medical 
Center, Omaha NE). Cell lines were authenticated using short tandem repeat (STR) profiling. KPC and 
KPCMfl/+ cell lines were gifts from Drs. Jennifer P. Morton, Owen J. Sansom, and Michael A. 
Hollingsworth. All pancreatic cancer cell lines were tested for Mycoplasma using PCR-based strategies 
and grown in DMEM+10% FBS at 37°C in a 5% CO2 atmosphere. All experiments were performed 
within 6-8 cell passages after thaw. HPNE cells were grown as previously described (8). KPC or 
KP(R172H/+)C denotes cells generated from Pdx1-Cre;LSL-KrasG12D;LSL-TP53R172H mice and KP(fl/fl)C 
denotes cells generated from Pdx1-Cre;LSL-KrasG12D;LSL-TP53fl/fl mice. To generate primary human 
PDA cell lines, PDA tissue from patient derived xenografts was collected in collaboration with the 
Brenden-Colson Center for Pancreatic Care and the Oregon Pancreas Tissue Registry as previously 
described (23) and mechanically disassociated and cultured in DMEM +10% FBS. Each primary human 
cell line is denoted with a unique Oregon Pancreas Tissue Registry (OPTR) number. Samples generated 
from metastatic patient tissue are denoted with an “M”. Transient knockdowns were performed using 
siRNA to c-Myc (SI00300902, Qiagen) and PPP2R5A (PP2A B56a; L009352, Dharmacon) using 
Dharma-FECT1 (Dharmacon) or Lipofectamine 3000 (Invitrogen) transfection reagents, respectively. 
Nontargeting siRNA (siNT) (1027310, Qiagen) was used as a control. Cells were plated into viability 
assays or for western blot analysis 24 hours after being treated with siRNA. For overexpression studies, 
cells were treated for 24 hours with either adenovirus encoding GFP or an adenovirus encoding GFP and 
MycT58A in DMEM+2% FBS. Viral load was adjusted for equal expression of GFP. Transfected cells 
were then used in viability assays or western blot analysis. 
 
 6 
Viability and Cytotoxicity Assays. Cells were plated in DMEM with 2% FBS in 96 well plates at 3,000 
cells per well. 24 hours post-plating, cells were treated with a 9-point dose dilution of the indicated 
inhibitor, either as a single agent or in combination, with DMSO as a control. After 72 hours, viability 
was measured using [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) CellTiter 96 cell viability kit (Promega). Combination Indices (CI) were calculated 
using the Chou and Talalay method (24) with CalcuSyn software (CalcuSyn). Details of the cytotoxicity 
assays can be found in the Supplemental Methods. The therapeutic compounds used were as follows: 
OP449 (25) and DT1154 (16) were described previously. BEZ235, INK128, GDC-0068, PP242, 
CUDC101, VX680, XL880, and Dasatinib were purchased from Selleck Chem. 
 
Quantitative PCR 
RNA was isolated using the RNAeasy Isolation Kit (Qiagen) from PANC89 cells treated with either 
Vehicle, 10µM DT1154, 0.5 µM INK128, or the combination of DT1154 and INK128 for 6 hours. cDNA 
was made as described previously (8) and quantitative PCR (qPCR) was performed using SYBR Green 
reagent (Invitrogen). Primers: MYC (F: 5′-CAGTGGGCTGTGAGGAGGTT-3′, R: 5′-
CAGGCTCCTGGCAAAAGGT-3′), NCL (Nucleolin) (5′-ACTGACCGGGAAACTGGGTC-3′, R: 5′-
TGGCCCAGTCCAAGGTAACT-3′), E2F2 (F: 5′-ACAAGGCCAACAAGAGGCTG-3′, R: 5′-
TCAGTCCTGTCGGGCACTTC-3′) and PPP2R5A (F: 5’-AGAGCCCTGATTTCCAGCCTA-3’, R: 5’-
TTTCCCATAAATTCGGTGCAGA-3’). The relative fold change relative to Vehicle was analyzed using 
the ΔΔ(CT) method described previously(26). 
 
Soft Agar Assay 
For soft agar assays, 1.4% noble agar was mixed 1:1 with 2X DMEM with 4% FBS and plated in 12 well 
plates. Cells were harvested and 40,000 cells were resuspended in 2X DMEM with 4% FBS. The cell 
suspension was then mixed 1:1 with 0.7% noble agar and plated on top of the base agar layer. Plates were 
fed twice a week with DMEM medium containing 2% FBS and either Vehicle or the indicated doses of 
DT1154, INK128, or combination. Plates were stained with 0.5 ml 0.005% crystal violet over night at 4oC 
and the total number of colonies was quantified in triplicate wells using ImageJ.  
 
Xenografts and Immunohistochemistry. All animal studies were performed in compliance with OHSU 
animal use guidelines after approval by the OHSU IACUC. PANC89, KPC, and KPC Mycfl/+ cells were 
resuspended in 50/50 serum free DMEM/growth factor reduced Matrigel (BD Biosciences) and 0.5M 
cells were subcutaneously injected into the flank of NSG mice. Once tumors were palpable, mice were 
randomized into treatment arms (Vehicle, DT1154 (100mg/kg), INK128 (0.5 mg/kg) or combination). 
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Each drug or Vehicle was administered once daily, six days a week by oral gavage (o.g.). For long-term 
studies, all mice were sacrificed when any tumor reached 2 cm in diameter. For short-term studies, all 
mice were sacrificed after 1 week of treatment and tumor tissue was either processed for formalin fixed 
paraffin embedding (FFPE) or snap frozen. For histological analysis, 6µM-thick FFPE sections were 
stained with hematoxylin and eosin (H/E). Full tumor H/E sections for each treatment condition were 
scanned using the Aperio (Leica Biosystems) and necrotic area was outlined and quantified using ImageJ. 
Apoptosis was detected using the ApopTag Plus Peroxidase In Situ Kit (Millipore, S7101). The number 
of TUNEL positive cells per 20X high power field (HPF) was quantified using ImageJ.  
 
Western Blot, Phosphokinase Array, and Immunoprecipitation. Pancreatic cancer cells were plated in 
DMEM with 2% FBS and 24 hours later treated with either Vehicle, 10µM DT1154, 0.5 µM INK128, or 
the combination of DT1154 and INK128 for 6 hours. Cells were lysed, run on an SDS page gel, and 
quantified using a LI-COR Odyssey as previously described (23). For tumor cell lysates, 50-150mg of 
tumor tissue was homogenized, lysed, and run as above. For the phosphokinase array (R&D Systems), 
PANC89 cells were treated and lysed as above and then 450 µg of protein per membrane was used per the 
kit protocol. Details of the MYC immunoprecipitation can be found in the Supplemental Methods. The 
following antibodies were used for western blot analysis: c-MYC (Y69 ab32072, Abcam; N-262 SC-764, 
Santa Cruz Biotechnology), pS62 MYC (ab78318, Abcam), pT58 MYC (Y011034, Applied Biological 
Materials), pAKT (CS4060, Cell Signaling Technology), AKT (CS2920, Cell Signaling Technology), 
pPRAS40 (CS2997, Cell Signaling Technology), PRAS40 (CS2691, Cell Signaling Technology), pS6 
(CS4858, Cell Signaling Technology), 4EBP1 (CS9644, Cell Signaling Technology), GAPDH (AM4300, 
Applied Biosystems), IRDye800 (Rockland), and Alexa Fluor 680 (Molecular Probes). GAPDH and 
secondary antibodies were used at 1:10,000 and all other primary antibodies were used at 1:1000. 
 
Statistical Analysis. P values were determined by two-tailed Student t test or ANOVA, as denoted in the 
figure legends. A P value of <0.05 was used to determine statistical significance. Error bars represent the 
standard error of the mean or standard deviation, as denoted in the figure legend. 
 
Results 
PP2A activation increases the cytotoxic effects of select kinase inhibitors. To identify oncogenic 
pathways susceptible to kinase inhibition and phosphatase activation, we analyzed the response of five 
human PDA cell lines in a kinase inhibitor screen with or without a low dose of OP449, a SET inhibitor 
that activates PP2A (27). Cell viability was assessed by MTS after three days and IC50s were calculated 
for both single agent and combination arms. PDA cell lines showed variable responses to single agent 
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kinase inhibitors, consistent with intertumoral phenotypic heterogeneity found in PDA tumors (Fig. S1A, 
Supplemental Table 1)(5). We identified several kinase inhibitors that displayed increased sensitivity with 
PP2A activation (Fig. S1B). Select oncogenic pathways known to contribute to PDA progression were 
validated in 96-well format, where VX-680 (Aurora), Dasatinib (Src family kinase), and INK128 (mTOR) 
inhibition showed the highest synergy using the Chou-Talalay method (Confidence Interval (CI) values 
less than 0.7) (Fig. 1A)(17, 24, 28-30). We focused on the PI3K/AKT/mTOR pathway as INK128 
showed the strongest synergy across cell lines, this pathway is regulated by PP2A at multiple points (31), 
and it is an important signaling node downstream of KRAS in PDA (19). We expanded our analysis to 
other kinase inhibitors within the PI3K/AKT/mTOR pathway to determine if the synergy between OP449 
and INK128 is specific to mTOR inhibition. Combination of OP449 with GDC0068 (AKT) or BKM120 
(PI3K) was synergistic in several lines, but compounds targeting mTOR (PP242 and INK128) resulted in 
the lowest CI values (Fig. 1B). These results suggest that mTOR inhibitors have increased efficacy in 
combination with PP2A activation compared to upstream inhibitors of the PI3K/AKT/mTOR pathway. 
Similar results were seen in a panel of breast cancer cell lines (Fig. S1C). Combination of INK128 and 
OP449 also resulted in increased cell death in PDA cells, as seen by flow cytometry for AnnexinV+ cells 
and a dose-dependent shift in viability curves (Fig. S1D, E). 
OP449 treatment reduces cell survival in several cancer types; however, SET inhibition is an 
indirect method of PP2A activation (8, 12, 26, 32). Consistent with our OP449 results, direct PP2A 
activation using the small-molecule activator, DT1154, reduced cell viability in all PDA cell lines tested, 
including two low-passage cell lines generated from patient derived xenograft tumors (OPTR4090-M and 
OPTR4136) (Fig. 1C, Fig. S2A)(16). INK128 reduced cell viability by 65% across PDA cell lines (Fig. 
1C), but was unable to drive apoptosis, as determined by absence of CellTox Green (Fig. 1D). 
Combination of DT1154 and INK128 synergistically reduced viability in multiple PDA cell lines (Fig. 
S2B, C), but not in the immortalized, non-transformed pancreatic cell line, HPNE (Fig. S2B-open 
circles). The combination of DT1154 and INK128 also significantly increased apoptosis over single agent 
treatments (Fig. 1D) and resulted in a dose-dependent shift of the MTS viability curves (Fig. S2C). To 
determine if PP2A activation and mTOR inhibition attenuates the ability of PDA cells to grow in an 
anchorage-independent environment, HPAFII and CFPAC1 cells were grown in soft agar and treated with 
Vehicle, DT1154, INK128, or the combination. The combination of DT1154 and INK128 significantly 
reduced colony formation over single agent treatment (Fig. 1E). Together, these results suggest that 
phosphatase activation and mTOR inhibition can function synergistically to reduce PDA cell survival and 
transformed phenotypes in vitro. 
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Combination of DT1154 and INK128 synergistically attenuates AKT/mTOR oncogenic signaling. 
To elucidate the signaling mechanisms underlying the synergy of PP2A activation and mTOR inhibition, 
PANC89 cells were treated with DT1154 and/or INK128 for 6 hours and the phosphorylation state of 38 
kinases were screened using a phosphokinase array. The fold intensity of each phosphorylation site 
relative to Vehicle was calculated and visualized by KMeans clustering (Fig. 2A; Supplemental Table 2). 
b-Catenin, STAT5a, PRAS40, p70 S6 Kinase, STAT3, WNK1, HSP60, and p53 (Cluster 2) were the only 
proteins with phosphorylation sites significantly decreased in combination-treated cells compared to 
single agent treatments (Fig. 2A inset, Fig. S3A). Using Pathway Commons through the CBio Portal (33, 
34) we determined that 7 of the 8 proteins in Cluster 2 are functionally linked to the PI3K/AKT/mTOR 
signaling pathway (Fig. 2B- Cluster 2 proteins noted with star), therefore we focused our analysis on this 
signaling node. Treatment with INK128 resulted in an almost complete loss of phosphorylation of the 
mTOR effectors S6 and 4EBP1, and reduced pAKT, but the combination of DT1154 and INK128 further 
decreased the levels of pAKT and pPRAS40, an mTOR inhibitor that is inactive in its phosphorylated 
state (Fig. 2C, S3B). Similar results were seen in a low-passage, primary human PDA cell line treated 
with DT1154 and INK128, as well as in PANC89 cells treated with OP449 and INK128 (Fig. S3C, D). 
Together, these results suggest that the combination of PP2A activation and mTOR inhibition more 
effectively suppresses the AKT/mTOR signaling node over single agent treatments.  
 
PP2A activation suppresses MYC mediated resistance to mTOR inhibition. Several signaling 
mechanisms have been suggested to increase resistance to PI3K-mTOR inhibitors, including AKT 
feedback loops, mTOR mutation, and increased MYC signaling (35-37). We have previously shown that 
SET inhibition, results in decreased MYC expression in breast and pancreatic cancer cell lines (8, 26). 
Additionally, MYC, mTOR, CIP2A, SET, and PP2A are frequently deregulated in PDA and altered 
expression of these factors is associated with poor survival (Fig. S4A, B). To determine if the 
combination of DT1154 and INK128 alters MYC expression, PDA cells were treated with DT1154 and/or 
INK128 for 6 hours and total MYC levels were analyzed. As expected, DT1154 treatment decreased total 
MYC levels in PANC89 and HPAFII cells. INK128 had variable effects on MYC levels, but the 
combination of DT1154 and INK128 further decreased MYC expression relative to either single agent 
treatment alone, thus resulting in a MYCLow/mTORLow state in the PANC89 and HPAFII cells (Fig. 3A, 
B). In contrast, MYC levels remained relatively constant across treatment arms in MIAPACA2 (MPC2) 
and PANC1 cells; although these cell lines displayed decreased activation of AKT and mTOR signaling 
with combination treatment, they did not show combination synergy (CI= 0.89 and 0.88 respectively) 
(Fig. 3A, B, S2B and S3B). These results suggest that sustained MYC expression may provide a survival 
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advantage to cells with reduced AKT/mTOR signaling and that the loss of both pathways is necessary for 
decreased cell survival. 
MYC activity and stability is predominantly controlled by dynamic phosphorylation at S62 and 
T58, with dephosphorylation of S62 driving the proteosomal degradation of MYC (38). To determine if 
combination treatment decreased MYC phosphorylation, PANC89 and PANC1 cells were treated with 
DT1154 and/or INK128 for 6 hours and endogenous MYC was assayed for phosphorylation at S62 and 
T58. In PANC89 cells, both DT1154 and INK128 lead to the dephosphorylation of S62, but these levels 
were reduced further with the combination of DT1154 and INK128, suggesting that these compounds 
may regulate MYC function through non-redundant mechanisms. In contrast, pS62 levels remained 
unchanged in PANC1 cells (Fig. 3C). Similar results were seen with pT58 (Fig. S5), indicating that 
PANC89 cells have dynamic turnover of MYC, while PANC1 cells lack this regulation. The loss of MYC 
protein in PANC89 cells was not due to decreased MYC mRNA levels as MYC expression increased in 
response to PP2A activation, likely due to an alleviation of autoregulation feedback loops (39), 
supporting a posttranslational mechanism of regulation (Fig. 3D). Consistent with reduced MYC 
expression, MYC target genes, NCL (Nucleolin) and E2F2, were significantly decreased in combination-
treated cells, suggesting that MYC function is suppressed (Fig. 3D).  
Our lab has shown that the PP2A B’ subunit, PPP2R5A (B56a), targets PP2A to dephosphorylate 
MYC at S62 (40). To determine if attenuating PP2A results in increased MYC expression and resistance 
to mTOR inhibition, PANC89 cells were transfected with siRNA to B56a and then treated with 
increasing doses of INK128. Decreased expression of B56a (Fig. S6A) increased cell viability in 
INK128-treated cells compared to siNT (Fig. 3E). The increase in viability was not due a loss in INK128 
function, as we saw no difference in AKT/mTOR signaling in siB56a cells (Fig. S6B, 3F). Consistent 
with the role of B56a in MYC stabilization, knockdown of B56a significantly increased MYC expression 
compared to siNT in Vehicle and INK128 treated cells (Fig. S6B, 3F). Thus, despite having an almost 
complete loss of AKT/mTOR signaling, siB56a cells treated with INK128 showed a MYCHigh/mTORLow 
cell state associated with increased viability (Fig. S6B, 3F). Consistent with these results, knockdown of 
B56a in PANC89 cells also decreased the efficacy of DT1154, suggesting that the effects of DT1154 and 
INK128 on MYC expression in this cell line are significantly mediated through PP2A’s posttranslational 
regulation of MYC (Fig. S6C). To determine if aberrant expression of MYC alone can increase resistance 
of PANC89 cells to INK128, we overexpressed MycT58A, a phosphorylation mutant resistant to PP2A (38, 
41), and then treated cells with increasing concentrations of INK128. Similar to B56a knockdown, 
expression of MycT58A significantly increased the viability of INK128 treated PANC89 cells (Fig. 3G). 
mTOR activity was suppressed with INK128 irrespective of MYCT58A expression, resulting in a 
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MYCHigh/mTORLow cell state, again associated with increased viability (Fig. S6D, 3H). Together, these 
results suggest that resistance to mTOR inhibition is mediated, in part, through stabilization of MYC.  
 
Decreased MYC expression sensitizes PDA cells to mTOR inhibitors. We next sought to determine 
whether direct suppression of MYC increases the efficacy of mTOR inhibition, particularly in lines where 
DT1154 was unable to decrease MYC expression. Suppression of MYC using siRNA significantly 
increased the sensitivity of PANC1 cells to INK128 (Fig. 4A). Sensitivity to INK128 was even more 
pronounced in cells with heterozygous expression of Myc (Pdx1-Cre;LSL-KrasG12D;LSL-TP53R172H;Mycfl/+ 
(KPC Mycfl/+)) compared to KPC cells (Fig. 4B) (42). INK128 maintained its ability to suppress mTOR 
signaling in both PANC1 siMYC or KPC Mycfl/+ cells, consistent with MYCLow/mTORLow signaling and 
reduced viability (Fig. S7, 4C, D). Importantly, treatment of KPC Mycfl/+ cells with the combination of 
DT1154 and INK128 provided no additional benefit over INK128 alone (Fig. 4E right), as compared to 
KPC, where the combination was significantly more efficacious over either single agents (Fig 4E left). 
Treatment of KPC Mycfl/+ cells with a different mTOR inhibitor, BEZ235, resulted in a similar decrease 
in viability relative to KPC cells (Fig. S8A). In contrast, Mycfl/+ cells showed little to no increase in 
sensitivity in response to Dasatinib (SFK inhibitor) (Fig. S8B) and displayed increased resistance to 
Sunitinib (multi-RTK, VEGFR) (Fig. S8C), indicating that combined suppression of MYC and mTOR 
may result in a unique sensitivity. To determine whether the combined loss of Myc and mTOR results in 
decreased tumor growth in vivo, KPC and KPC Mycfl/+ cells were subcutaneously implanted and treated 
with either Vehicle or INK128. INK128 treatment had little to no effect on KPC tumors (Fig. 4F, G blue 
circles). In contrast, INK128 significantly reduced KPC Mycfl/+ tumor growth (Fig. 4F, G blue triangles).  
 
PP2A activation combined with mTOR inhibition decreases tumorigenic properties in vivo. We next 
determined whether the combination of DT1154 and INK128 would have anti-tumorigenic properties in 
vivo. PANC89 cells were injected subcutaneously and mice were treated with Vehicle, DT1154, INK128, 
or the combination. Consistent with our results in vitro, combination treatment significantly reduced 
tumor growth compared to either drug alone (Fig. 5A, B). In addition to decreased tumor size, histological 
analysis revealed a significant increase in tumor cell necrosis in combination-treated tumors relative to 
single agent or Vehicle-treated tumors (Fig. 5C, S9A). To assess apoptosis during therapeutic treatment, 
PANC89 cells were injected subcutaneously and tumors were harvested after 7 days of treatment with 
Vehicle, DT1154, INK128, or the combination. Similar to long-term treatment, short-term treatment with 
the combination of DT1154 and INK128 significantly decreased tumor growth and tumor weight, while 
simultaneously increasing necrosis (Fig. S9B-D). Combination treated tumors also displayed a significant 
increase in apoptotic (TUNEL+) cells within non-necrotic areas (Fig. 5D, S9E). To determine the effects 
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of combination treatment on oncogenic pathways, tumors were lysed and analyzed by western blot. 
Consistent with our results in vitro, single agent treatment with DT1154 reduced MYC expression, but 
was unable to significantly alter AKT/mTOR signaling. Conversely, INK128 was able to reduce mTOR 
signaling, but had minimal effects on MYC expression. In contrast, the combination of DT1154 and 
INK128 resulted in a significant loss of both MYC and AKT/mTOR signaling pathway (Fig 5E, F). 
Together, these data suggest that inhibition of mTOR signaling can reduce PDA cell survival 
through a loss of the AKT/mTOR pathway; however, cells can circumvent this loss by maintaining MYC 
signaling (Fig. 6A- MYCHigh/mTORLow). Combined loss of MYC and mTOR, through the use of PP2A 
activators and mTOR inhibitors, results in a more complete loss of oncogenic signaling and a synergistic 
decrease in cell viability (Fig. 6B- MYCLow/mTORLow).     
 
Discussion 
 Pancreatic tumors have a diverse mutational profile that contributes to the redundant activation of 
survival pathways, rendering single agent targeted therapies clinically ineffective and supporting 
combination therapeutic strategies (5). Suppression of phosphatases significantly contributes to oncogenic 
progression in multiple cells types and we have demonstrated that PDA cells have reduced PP2A activity 
compared to normal cells (8, 43, 44). Attenuated PP2A activity may facilitate the rewiring of oncogenic 
pathways in response to kinase inhibition, leading to therapeutic resistance. Our current results suggest 
that restoring PP2A function can impact multiple oncogenic pathways, potentially restricting cell 
plasticity and increasing dependency on specific kinase pathways. We show that PP2A activation can 
synergistically increase the efficacy of several kinase inhibitors in PDA cells. We focus on mTOR 
inhibition and demonstrate that combination with PP2A activation results in synergistic cell death of 
pancreatic cancer cells in vitro and in vivo. This synergy is associated with the suppression of key 
pathways attributed to cancer cell survival and therapeutic resistance, indicating that PP2A activation may 
prevent signaling plasticity in response to targeted kinase inhibition. 
  In our studies, PP2A activation displayed synergy with inhibitors of the PI3K/AKT/mTOR 
signaling node, a pathway that is regulated at several points by PP2A. Specifically, PP2A has been shown 
to dephosphorylate AKT, mTOR, and the mTOR effectors 4EBP1 and S6K and conversely, mTOR is 
able to suppress PP2A activity (6). Further, mTOR and PP2A have been shown to function in a reciprocal 
regulatory network with CIP2A (a PP2A inhibitor) and c-MYC (a PP2A target), where CIP2A attenuates 
PP2A activity, increasing signaling through mTOR and MYC and subsequently activating feedback loops 
that increase expression of mTOR, MYC, and CIP2A (45). Together, these studies suggest that cellular 
alterations that shift the balance of these factors can drive molecular changes that contribute to 
oncogenesis. Indeed, several studies have highlighted the importance of mTOR signaling in PDA 
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progression and aggressiveness, with components of the PI3K/AKT/mTOR pathway being altered in the 
majority of PDA patients (46).  
 While mTOR has been identified as an important target in PDA, several resistance mechanisms 
have been identified that decrease the clinical efficacy of mTOR inhibitors (21). Treatment with 
mTORC1 inhibitors, such as Rapamycin, can cause a significant increase in pAKT signaling, leading to 
therapeutic resistance. As such, compounds that target mTORC1 and 2 have displayed increased clinical 
efficacy, underscoring the importance of AKT inhibition to tumor cell survival. Here, we demonstrate that 
treating PDA cells with INK128, an mTORC1/2 inhibitor, results in almost a complete loss of mTORC1 
signaling (pS6 and 4EBP1) and a suppression of mTORC2 signaling (pAKT). Consistent with the role of 
PP2A in regulating AKT phosphorylation, DT1154 in combination with INK128 further reduced pAKT 
signaling over INK128 treatment alone. Additionally, AKT has been shown to phosphorylate the mTOR 
inhibitor, PRAS40, at T246, inhibiting PRAS40 function. We found a significant decrease in phospho-
PRAS40 in combination treated cells, indicating that AKT function is more completely suppressed. 
Together these studies suggest that increased PP2A activity in response to DT1154 can repress signaling 
plasticity and resistance that occurs in response to mTOR inhibition. These results are consistent with 
reports demonstrating that KPC mice are refractory to single agent mTOR inhibition and that combination 
therapy may be necessary to prolong survival (30).  
 The MYC oncoprotein plays an important role in tumor progression and therapeutic resistance in 
multiple cancer types (23, 47). In breast and prostate cancer, deregulated MYC expression increases 
resistance to PI3K/mTOR inhibitors (35, 36, 48). However, despite the known roles of MYC in 
resistance, therapeutic targeting of MYC remains a significant challenge. Here, treatment with DT1154, 
effectively reduced MYC levels in HPAFII and PANC89 cells. Furthermore, DT1154 combined with 
INK128 had a greater suppression of MYC in these cell lines. Interestingly, the combination of INK128 
and DT1154 was not synergistic in MIAPACA2 and PANC1 cells, where MYC expression was refractory 
to treatment, despite efficient suppression of pAKT/mTOR signaling, suggesting that a 
MYCHigh/mTORLow cell state represents a resistant subpopulation. Consistent with this hypothesis, 
suppression of PP2A B56a or expression of MycT58A, resulted in an increased resistance to INK128 and a 
MYCHigh/mTORLow cell state in INK128 treated PANC89 cells. Conversely, transient knockdown or 
genetic loss of one copy of MYC was able to restore a MYCLow/mTORLow cell state in PANC1 and KPC 
cells and sensitize these cells to INK128 both in vitro and in vivo. Our previous studies demonstrated that 
OP449 was unable to decrease MYC pS62 in PANC1 cells (8). This line also happened to have the 
highest expression of CIP2A and SET out of the panel of PDA cell lines we analyzed, relative to the 
normal pancreatic epithelial line HPNE, indicating that this line has acquired mechanisms to suppress 
PP2A function.  Future experiments will explore resistance mechanisms to DT1154 and investigate 
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strategies to re-activate PP2A in these settings. Together, these results suggest that PP2A activating 
compounds can function synergistically with mTOR inhibitors and that negative regulation of MYC is 
important in this context to suppress MYC-driven resistance pathways and create a MYCLow/mTORLow 
cell state that is less viable. 
 In conclusion, we demonstrate that therapeutic activation of PP2A can increase the efficacy of 
kinase inhibitors, in part by limiting signaling crosstalk and plasticity. Further, we identify MYC as a 
potential resistance mechanism by which PDA cells escape mTOR inhibition. While mTOR inhibitors are 
not currently used as standard of care in pancreatic cancer patients, future studies will determine if MYC 
expression may be a biomarker of response to mTOR inhibitors in solid tumors. 
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Fig. 1: PP2A activation increases the cytotoxic effects of select kinase inhibitors. A. CI values at effective 
dose (ED) 75 for pancreatic cells lines treated with increasing concentrations of OP449 and select kinase 
inhibitors. Mean +/- SEM of biological replicates. B. CI values at ED75 of ASPC1, MIAPACA2, and 
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PANC89 treated with INK128, PP242, BKM120, or GDC0068. Values for each cell line were generated 
from 2 (MIAPACA2- GDC0068) or 3 biological reps. Grand mean of all lines for each drug shown. C. 
PDA cell lines were treated with increasing doses of DT1154 (left) or INK128 (right) for 72 hours. 
Shown is the viability relative to Vehicle for each line. MIAPACA2 (MPC2) D. CellTox Green was 
added to HPAFII and PANC89 cells and then cells were treated with increasing concentrations of 
DT1154 and INK128. Fluorescent cells were imaged every 2 hours for 72 hours on an Incucyte Zoom. 
Shown is the area under the curve (AUC) generated from the green object count (1/mm2) over time 
relative to Vehicle control. Graph represents average of three biological replicates. ***P  <0.001 by a 2-
way ANOVA. E. HPAFII and CFPAC1 cells were plated in a soft agar colony assay and treated with 
Vehicle, 500nM DT1154, 10nM INK128, or combination. Colony number was quantified using ImageJ. 
Mean +/- SEM of three biological replicates. *p<0.05 by a two-tailed students t-test. 
 
Fig. 2: Combination of DT1154 and INK128 synergistically attenuates AKT/mTOR oncogenic signaling 
A. PANC89 cells were treated with Vehicle (V), DT1154 (D, 10µM), INK128 (I, 0.5µM), or the 
combination of DT1154 and INK (C) for 6 hours and cell lysates were probed using a phosphokinase 
array. Quantification of phospho-specific sites for each kinase relative to Vehicle control was used to 
generate a heat map using Morpheus and KMeans clustering was performed using one minus pearson 
correlation (Clusters 1-5). Phosphorylation sites, proteins, and expression values can be found in 
Supplemental Table 2. Inset shows the expression of the phosphorylated proteins in Cluster 2 relative to 
Vehicle control. Grand mean shown. ***p<0.001 **p<0.01 *p<0.05 by a 1-way ANOVA. B. A pathway 
Commons network map generated from targets in Cluster 2 using the QCMG, Nature 2016 dataset from 
CBio Portal. Complex, state change, expression, and alteration frequency between proteins are shown. 
Gene names of targets in Cluster 2 are denoted by a star. C. PANC89 and HPAFII cells were treated as in 
panel A and probed by western blot for pAKT (S473), pPRAS40 (T246), pS6 (S235/6) and totals. 
Representative blots and quantification of three biological replicates shown. Arrows indicate 
phosphorylated form of 4EBP1. pS6 quantified over GAPDH. Mean +/- SEM. *p<0.05 by two-tailed 
students t-test. 
 
Fig. 3: PP2A activation suppresses MYC mediated resistance to mTOR inhibition A and B. PANC89, 
HPAFII, MIAPACA2 (MPC2), and PANC1 cells were treated with Vehicle (V), DT1154 (D; 10µM), 
INK128 (I; 0.5µM), or the combination (C) for 6 hours and lysates were probed by western blot. 
Representative blot (A) and quantification over GAPDH (B) of three biological replicates shown. Mean 
+/- SEM C. PANC89 and PANC1 cells were treated as in Figure 3A. Total MYC was 
immunoprecipitated and lysates were probed for phosphoS62 MYC (pS62). Inputs were probed for total 
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MYC and GAPDH *denotes IgG heavy chain. Quantification of pS62 levels over GAPDH relative to 
Vehicle shown D. qPCR of MYC, NCL (Nucleolin), and E2F2 from PANC89 cells treated as in Figure 
3A. Mean +/- SEM of three biological replicates. E. PANC89 cells transfected with non-targeting siRNA 
(siNT) or a B56a targeting siRNA pool (siB56a) were treated with increasing concentrations of INK128. 
Viability was assessed by MTS 72 hours after drug treatment. Mean +/- SEM of three biological 
replicates. F. Cells from panel E were treated with either Vehicle or 0.5µM INK128 for 6 hours. Lysates 
were analyzed by western blot for MYC, pAKT (S473), pS6 (S235/6) and totals. Quantification from 
three biological replicates is shown. Mean +/- SD. G. PANC89 cells transfected with AdGFP (GFP) or 
AdMYCT58A (T58A) were treated with increasing concentrations of INK128. Viability was assessed by 
MTS 72 hours after drug treatment. Mean +/- SEM of three biological replicates. H. Cells from panel G 
were treated with either Vehicle or 0.5µM INK128 for 6 hours. Lysates were analyzed by western blot as 
above. Quantification from three biological replicates is shown. Mean +/-SD. For all panels ***p<0.001 
**p<0.01 *p<0.05 by two-tailed students t-test; #, & denotes pS6 or pAKT levels, respectively, are 
significantly different in INK128 conditions compared to Vehicle. 
 
Fig. 4: Decreased Myc expression sensitizes PDA cells to mTOR inhibition in vitro and in vivo A. 
PANC1 cells transfected with non-targeting siRNA (siNT) or MYC targeting siRNA (siMYC) were 
treated with increasing concentrations of INK128. Viability was assessed by MTS 72 hours after drug 
treatment. Mean +/-SEM of three biological replicates. B. Cells derived from KPC or KPC Mfl/+ mice 
were treated with increasing concentrations of INK128. Viability was assessed by MTS 72 hours after 
drug treatment. Mean +/-SEM of three biological replicates. C. Cells from panel A (siNT or siMYC) and 
D. cells from panel B (KPC or KPC Mfl/+) were treated with either Vehicle or 0.5µM INK128 for 6 hours. 
Lysates were analyzed by western blot for MYC, pAKT (S473), pS6 (S235/6) and totals. Quantification 
from three biological replicates is shown. Mean +/-SEM. E. KPC (left) and KPC Mfl/+ (right) cells were 
treated with either Vehicle or increasing concentrations of DT1154, INK128, or the combination for 72 
hours. Viability relative to Vehicle was assessed by MTS. Average of 4 replicates across 2 biological 
experiments shown. Mean +/-SEM. For all panels ***p<0.001 **p<0.01 *p<0.05 by two-tailed students 
t-test. #, & denotes pS6 or pAKT levels, respectively, are significantly different in INK128 conditions 
compared to Vehicle. F. KPC and KPC Mfl/+ cells were injected subcutaneous and then treated with either 
Vehicle or INK128 (0.5 mg/kg oral gavage, once a day/6 days a week). Tumor volume was measured 
across time. Mean +/- SEM. n= 8 KPC, 8 KPC+INK128, 7 KPC Mfl/+, 8 KPC Mfl/++INK128. G. 
Quantification of end point tumor size from panel F. **p<0.01 by two-tailed students t-test   
 
 19 
Fig. 5: PP2A activation combined with mTOR inhibition decreases tumorigenic properties in vitro and in 
vivo A. PANC89 were grown subcutaneously and mice were treated with Vehicle, DT1154 (15mg/kg), 
INK128 (0.5 mg/kg), or combination. Tumors were calipered and tumor volume was plotted across time. 
Mean +/- SEM shown. n= 6 Vehicle, 8 DT1154, 6 INK128, and 9 combination treated tumors. Area 
under the curve was analyzed for each treatment arm, *p<0.05 by a 1-way ANOVA B. Quantification of 
end point tumor size from panel B. Mean +/- SEM shown. C. Quantification of necrotic tumor area from 
H/E images using ImageJ. Mean +/- SEM shown. D. PANC89 xenograft tumors were grown as in panel 
A and harvested after 7 days of treatment with Vehicle (Veh), DT1154 (DT, 15mg/kg), INK128 (INK, 0.5 
mg/kg), or combination (Combo). Tissues sections were stained with the ApopTag Plus Peroxidase In 
Situ Kit and the number of TUNEL positive cells was quantified per high-powered field (HPF, 20x). 
***p<0.001 *p<0.05 by a 1-way ANOVA. E. Lysates from tumors grown in panel D were analyzed by 
western blot for MYC, pAKT (S473), pS6 (S235/6), 4EBP1, and totals. F. Quantification of 3 tumors in 
each treatment group from panel E shown. Mean +/-SEM. **p<0.01 *p<0.05 by two-tailed students t-test   
 
Fig. 6: PP2A activation combined with mTOR inhibition as a therapeutic strategy to reduce PDA 
survival. A. Oncogenic KRAS drives the activation of both the MYC and PI3K/AKT/mTOR pathways. 
Upon mTOR inhibition, PDA cells capitalize on low PP2A levels, signaling through MYC for survival, 
creating a MYCHigh/mTORLow cell state. B. Activation of PP2A combined with mTOR inhibition results 


















































































































































































































































Fig. 1: PP2A activation increases the cytotoxic effects of select kinase inhibitors. A. CI values at effective 
dose (ED) 75 for pancreatic cells lines treated with increasing concentrations of OP449 and select kinase 
inhibitors. Mean +/- SEM of biological replicates. B. CI values at ED75 of ASPC1, MIAPACA2, and 
PANC89 treated with INK128, PP242, BKM120, or GDC0068. Values for each cell line were generated 
from 2 (MIAPACA2- GDC0068) or 3 biological reps. Grand mean of all lines for each drug shown. C. 
PDA cell lines were treated with increasing doses of DT1154 (left) or INK128 (right) for 72 hours. 
Shown is the viability relative to Vehicle for each line. MIAPACA2 (MPC2) D. CellTox Green was 
added to HPAFII and PANC89 cells and then cells were treated with increasing concentrations of 
DT1154 and INK128. Fluorescent cells were imaged every 2 hours for 72 hours on an Incucyte Zoom. 
Shown is the area under the curve (AUC) generated from the green object count (1/mm2) over time 
relative to Vehicle control. Graph represents average of three biological replicates. ***P  <0.001 by a 2-
way ANOVA. E. HPAFII and CFPAC1 cells were plated in a soft agar colony assay and treated with 
Vehicle, 500nM DT1154, 10nM INK128, or combination. Colony number was quantified using ImageJ. 
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Fig. 2: Combination of DT1154 and INK128 synergistically attenuates AKT/mTOR oncogenic signaling 
A. PANC89 cells were treated with Vehicle (V), DT1154 (D, 10µM), INK128 (I, 0.5µM), or the 
combination of DT1154 and INK (C) for 6 hours and cell lysates were probed using a phosphokinase 
array. Quantification of phospho-specific sites for each kinase relative to Vehicle control was used to 
generate a heat map using Morpheus and KMeans clustering was performed using one minus pearson 
correlation (Clusters 1-5). Phosphorylation sites, proteins, and expression values can be found in 
Supplemental Table 2. Inset shows the expression of the phosphorylated proteins in Cluster 2 relative to 
Vehicle control. Grand mean shown. ***p<0.001 **p<0.01 *p<0.05 by a 1-way ANOVA. B. A pathway 
Commons network map generated from targets in Cluster 2 using the QCMG, Nature 2016 dataset from 
CBio Portal. Complex, state change, expression, and alteration frequency between proteins are shown. 
Gene names of targets in Cluster 2 are denoted by a star. C. PANC89 and HPAFII cells were treated as in 
panel A and probed by western blot for pAKT (S473), pPRAS40 (T246), pS6 (S235/6) and totals. 
Representative blots and quantification of three biological replicates shown. Arrows indicate 
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Fig. 3: PP2A activation suppresses MYC mediated resistance to mTOR inhibition A and B. PANC89, 
HPAFII, MIAPACA2 (MPC2), and PANC1 cells were treated with Vehicle (V), DT1154 (D; 10µM), 
INK128 (I; 0.5µM), or the combination (C) for 6 hours and lysates were probed by western blot. 
Representative blot (A) and quantification over GAPDH (B) of three biological replicates shown. Mean 
+/- SEM C. PANC89 and PANC1 cells were treated as in Figure 3A. Total MYC was 
immunoprecipitated and lysates were probed for phosphoS62 MYC (pS62). Inputs were probed for total 
MYC and GAPDH *denotes IgG heavy chain. Quantification of pS62 levels over GAPDH relative to 
Vehicle shown D. qPCR of MYC, NCL (Nucleolin), and E2F2 from PANC89 cells treated as in Figure 
3A. Mean +/- SEM of three biological replicates. E. PANC89 cells transfected with non-targeting siRNA 
(siNT) or a B56α targeting siRNA pool (siB56α) were treated with increasing concentrations of INK128. 
Viability was assessed by MTS 72 hours after drug treatment. Mean +/- SEM of three biological 
replicates. F. Cells from panel E were treated with either Vehicle or 0.5µM INK128 for 6 hours. Lysates 
were analyzed by western blot for MYC, pAKT (S473), pS6 (S235/6) and totals. Quantification from 
three biological replicates is shown. Mean +/- SD. G. PANC89 cells transfected with AdGFP (GFP) or 
AdMYCT58A (T58A) were treated with increasing concentrations of INK128. Viability was assessed by 
MTS 72 hours after drug treatment. Mean +/- SEM of three biological replicates. H. Cells from panel G 
were treated with either Vehicle or 0.5µM INK128 for 6 hours. Lysates were analyzed by western blot as 
above. Quantification from three biological replicates is shown. Mean +/-SD. For all panels ***p<0.001 
**p<0.01 *p<0.05 by two-tailed students t-test; #, & denotes pS6 or pAKT levels, respectively, are 
significantly different in INK128 conditions compared to Vehicle. 
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Fig. 4: Decreased Myc expression sensitizes PDA cells to mTOR inhibition in vitro and in vivo A. 
PANC1 cells transfected with non-targeting siRNA (siNT) or MYC targeting siRNA (siMYC) were 
treated with increasing concentrations of INK128. Viability was assessed by MTS 72 hours after drug 
treatment. Mean +/-SEM of three biological replicates. B. Cells derived from KPC or KPC Mfl/+ mice 
were treated with increasing concentrations of INK128. Viability was assessed by MTS 72 hours after 
drug treatment. Mean +/-SEM of three biological replicates. C. Cells from panel A (siNT or siMYC) and 
D. cells from panel B (KPC or KPC Mfl/+) were treated with either Vehicle or 0.5µM INK128 for 6 hours. 
Lysates were analyzed by western blot for MYC, pAKT (S473), pS6 (S235/6) and totals. Quantification 
from three biological replicates is shown. Mean +/-SEM. E. KPC (left) and KPC Mfl/+ (right) cells were 
treated with either Vehicle or increasing concentrations of DT1154, INK128, or the combination for 72 
hours. Viability relative to Vehicle was assessed by MTS. Average of 4 replicates across 2 biological 
experiments shown. Mean +/-SEM. For all panels ***p<0.001 **p<0.01 *p<0.05 by two-tailed students 
t-test. #, & denotes pS6 or pAKT levels, respectively, are significantly different in INK128 conditions 
compared to Vehicle. F. KPC and KPC Mfl/+ cells were injected subcutaneous and then treated with either 
Vehicle or INK128 (0.5 mg/kg oral gavage, once a day/6 days a week). Tumor volume was measured 
across time. Mean +/- SEM. n= 8 KPC, 8 KPC+INK128, 7 KPC Mfl/+, 8 KPC Mfl/++INK128. G. 















































































































































Fig. 5: PP2A activation combined with mTOR inhibition decreases tumorigenic properties in vitro and in 
vivo A. PANC89 were grown subcutaneously and mice were treated with Vehicle, DT1154 (15mg/kg), 
INK128 (0.5 mg/kg), or combination. Tumors were calipered and tumor volume was plotted across time. 
Mean +/- SEM shown. n= 6 Vehicle, 8 DT1154, 6 INK128, and 9 combination treated tumors. Area 
under the curve was analyzed for each treatment arm, *p<0.05 by a 1-way ANOVA B. Quantification of 
end point tumor size from panel B. Mean +/- SEM shown. C. Quantification of necrotic tumor area from 
H/E images using ImageJ. Mean +/- SEM shown. D. PANC89 xenograft tumors were grown as in panel 
A and harvested after 7 days of treatment with Vehicle (Veh), DT1154 (DT, 15mg/kg), INK128 (INK, 0.5 
mg/kg), or combination (Combo). Tissues sections were stained with the ApopTag Plus Peroxidase In 
Situ Kit and the number of TUNEL positive cells was quantified per high-powered field (HPF, 20x). 
***p<0.001 *p<0.05 by a 1-way ANOVA. E. Lysates from tumors grown in panel D were analyzed by 
western blot for MYC, pAKT (S473), pS6 (S235/6), 4EBP1, and totals. F. Quantification of 3 tumors in 

























Fig. 6: PP2A activation combined with mTOR inhibition as a therapeutic strategy to reduce PDA 
survival. A. Oncogenic KRAS drives the activation of both the MYC and PI3K/AKT/mTOR pathways. 
Upon mTOR inhibition, PDA cells capitalize on low PP2A levels, signaling through MYC for survival, 
creating a MYCHigh/mTORLow cell state. B. Activation of PP2A combined with mTOR inhibition results 
in low MYC and mTOR signaling in a MYCLow/mTORLow cell state, decreasing PDA cell survival. 


































































































































































































A B IC50 Fold  
decrease with OP449 
A M P P89 H
1.20 2.69 2.19 0.55 50.18
1.74 3.30 1.91 3.14 0.41
3.55 1.12 3.71 0.85 0.11
1.02 8.42 1.00 0.33 1.40
1.00 1.00 1.00 7.94 0.16
0.58 1.15 2.29 0.60 0.08
1.00 1.12 1.05 1.66 2.86
2.05 1.27 0.63 5.72 1.07
0.83 2.14 1.00 0.56 4.90
2.46 1.17 1.00 15.25 1.76
9.76 2.03 1.00 3.70 0.45
1.00 33.00 1.00 2.24 1.00
3.98 1.71 2.63 0.00 6.14
0.84 0.59 1.00 4.19 1.51
1.72 3.71 2.49 1.83 0.55
0.19 3.02 3.11 0.58 1.62
1.66 2.62 1.17 2.21 0.96
1.00 8.90 1.00 1.00 1.00
1.00 1.00 1.00 1.00 8.50
0.34 2.88 1.00 2.24 1.00
1.37 1.67 1.10 3.06 1.29
1.40 2.95 2.09 1.81 0.53
1.00 0.13 3.80 159.59 320.52
3.16 0.73 0.98 23.31 23.37
1.00 1.29 1.00 1.00 4.07
1.00 8.46 1.00 0.96 1.99
1.00 7.39 1.00 4.46 1.29
1.00 4.26 1.00 1.48 1.00
1.35 0.43 1.55 1.23 0.48
1.00 4.61 1.00 3.34 1.21
1.96 1.31 1.90 6.31 1.02
1.23 81.60 1.00 4.67 21.79
0.30 2.14 1.00 3.43 0.79
1.00 46.56 1.00 28.10 1.00
5.01 0.93 1.00 1.23 0.85
1.00 1.00 1.00 0.79 1.00
0.93 7.67 3.39 0.50 2.82
1.35 4.66 1.23 2.30 3.52
1.00 3.16 1.00 13.17 1.00
0.28 3.51 1.00 0.09 0.04
0.76 4.46 1.00 2.24 12.71
1.00 12.87 1.00 22.86 1.00
2.95 3.02 1.00 1.00 0.63
0.36 1.00 1.23 1.23 0.64
0.16 1.48 1.00 0.34 0.49
1.26 3.45 1.00 1.99 2.62
1.59 1.33 1.00 1.79 0.22
1.00 0.14 1.00 17.35 107.42
1.15 1.51 1.00 1.17 0.87
1.23 6.45 1.35 0.79 2.45
1.00 0.67 1.00 1.00 0.09
1.00 31.96 1.00 0.73 1.00
6.45 3.80 2.09 1.15 22.27
2.13 0.98 1.00 0.42 55.92
0.09 2.41 1.62 0.40 0.41
1.00 2.24 1.00 3.39 1.00
3.45 0.01 1.00 1.00 1.08
1.22 1.09 1.00 0.37 1.11
2.40 5.12 2.04 11.71 0.91
1.00 1.00 1.00 1.82 5.89
4.25 2.33 0.51 3.38 0.85
6.36 1.29 1.00 0.18 1.20
1.82 0.45 1.00 0.33 0.93
3.02 6.75 1.00 1.00 0.04
4.17 1.58 1.00 3.47 0.17
1.00 1.99 1.00 15.82 1.00
0.71 0.85 1.00 1.72 0.96
1.00 2.95 1.00 0.95 1.00
1.00 0.80 0.91 1.00 0.05
0.52 2.50 1.07 33.52 0.72
0.59 4.17 1.12 3.89 0.56
0.54 2.56 1.00 16.06 0.41
3.02 1.07 1.00 0.63 1.00
1.41 1.00 4.17 0.85 0.52
1.12 2.76 1.00 3.82 0.22
1.00 1.00 1.00 6.91 1.00
1.66 1.70 2.24 0.63 0.33
1.00 1.05 1.00 0.72 1.00
0.89 2.81 1.41 3.54 0.65
1.07 0.95 0.98 5.08 1.00
2.43 0.46 1.00 0.56 1.00
1.99 1.35 3.16 0.83 0.55
1.23 1.00 1.00 8.30 0.03
1.00 1.00 1.00 2.29 1.00
1.62 1.12 2.57 1.58 6.55
0.15 3.26 4.57 0.55 0.22
1.17 30.75 1.00 1.80 1.00
1.00 1.00 1.00 0.27 8.90
1.00 204.65 1.00 1.12 1.00
1.00 4.75 1.00 2.29 0.25
1.00 8.50 1.00 0.57 0.86
1.78 1.10 1.00 0.49 2.51
1.00 1.00 1.00 10.73 1.78
1.00 17.24 1.00 0.93 1.00
1.00 1.00 1.00 1.66 1.00
1.00 0.93 1.00 1.00 1.00
1.00 1.00 1.00 1.40 1.00
1.00 0.96 1.00 8.59 1.00
1.00 3.89 1.00 1.00 1.00
1.00 12.57 1.00 6.30 1.00
1.00 0.76 1.38 1.23 1.00
1.00 374.48 1.00 0.50 1.00
0.81 0.62 1.35 2.95 8.87
1.21 1.11 1.20 0.40 0.76
16.19 0.91 1.00 1.00 38.06
1.45 3.01 1.00 0.22 0.59
1.35 1.17 1.00 133.85 0.74
2.40 1.00 1.00 1.00 1.02
1.12 1.00 1.00 0.26 1.00
1.00 0.96 1.00 1.58 1.00
0.44 0.90 3.76 0.09 0.23
1.00 2.69 1.00 1.00 1.00
1.25 1.28 1.65 1.11 0.92
1.00 1.00 1.00 1.00 1.00
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Supplemental Figure 1 
Fig. S1: OP449 functions synergistically with specific kinase inhibitors in PDA cell lines A 
and B. PDA cell lines were plated into 384-well kinase inhibitor plates with or without OP449 
and 72 hours later viability was assessed by MTS. A. Single agent kinase inhibitors without 
OP449 were ranked by the median IC50 across all the PDA lines for each individual drug 
relative to vehicle control. IC50s generated from PANC89, HPAFII, ASPC1, MiaPaca2, and 
PANC1 were then plotted individually based on the ranked list generated above. B. Relative 
fold decrease in IC50 of each kinase inhibitor with the addition of OP449 in ASPC1 (A), 
MiaPaca2 (M), PANC1 (P), PANC89 (P89), and HPAFII (H) PDA cells. Each row represents a 
different kinase inhibitor. A detailed list of inhibitor names and IC50s can be found in 
Supplemental Dataset 1. C. Breast cancer cell lines were plated in viability assays and 
treated with increasing doses of OP449 and INK128, BKM120, or GDC0068CI. The mean CI 
value of two biological replicates at effective dose (ED)75 for each line is shown. D. 
MiaPaca2 (MPC2)(OP449 3µM, INK128 2µM), PANC1 (OP449 3mM, INK128 1µM), PANC89 
(OP449 1µM, INK128 1µM), and primary human cell line OPTR3099 (OP449 1µM, INK128 
1µM) were treated with the indicated doses of OP449 and INK128 for 48 hours. Annexin V+ 
cells in each condition were then quantified and the relative fold was calculated for each cell 
line. E. PDA cell lines were treated with vehicle or increasing doses of OP449 and/or INK128 
for 72 hours. Viability was assessed by MTS and viability curves were generated with 
CalcuSyn software. Representative curves of two or more biological replicates shown. 





















































































































Supplemental Figure 2 
Fig S2: OP449 functions synergistically mTOR inhibition in PDA cell lines A. PDA cell lines 
were treated for 72 hours with OP449 or DT1154 and then viability was assessed by MTS. 
IC50s were generated with CalcuSyn software. B. PDA cell lines, as well as a normal 
pancreatic epithelial cell line (HPNE), were treated with vehicle or increasing doses of 
DT1154 and/or INK128 for 72 hours. Viability was assessed by MTS and CI values at 
effective dose (ED)50 and ED75 were generated with CalcuSyn software. CI values for 
each line were generated from 2 (HPNE/KPC) or 3+ biological replicates. C. PDA cell lines 
were treated with vehicle or increasing doses of DT1154 and/or INK128 for 72 hours. 
Viability was assessed by MTS and viability curves were generated with CalcuSyn 
software. Representative curves of two or more biological replicates shown. 
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Supplemental Figure 3 
Fig. S3: PP2A activation and mTOR inhibition decreases AKT/mTOR signaling A. Expression of 
the phosphorylated proteins in Clusters 1, 3, 4, and 5, generated in Fig. 3, relative to vehicle 
control. Grand mean shown. ***p<0.001 **p<0.01 *p<0.05 by a 1-way ANOVA. B. MiaPaca2 
(MPC2) and PANC1 cells were treated with Vehicle, DT1154 (10µM), INK128 (0.5µM), or the 
combination of DT1154 and INK for 6 hours and cell lysates were probed by western blot.  
Representative blots and quantification of three biological replicates shown. Mean +/- SEM. C.  
The primary human cell line, OPTR4136, was treated with vehicle (Veh), DT1154 (DT; 2.5µM), 
INK128 (INK1 (1µM),  INK2 (2µM)), or the combination of DT1154 and INK128 (C1 and C2) for 4 
hours and then probed by western blot. D. PANC89 cells were treated with vehicle (Veh), OP449 
(OP; 0.5µM), INK128 (INK; 0.5µM,  1mΜ), or the combination of OP449 and INK128 for 48 
hours and then probed by western blot. Representative of two experiments.  
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Genetic Alteration Missense Mutation (unknown significance) Amplification Gain Shallow Deletion mRNA Upregulation
mRNA Downregulation Protein Upregulation No alterations
A 
B 
Supplemental Figure 4 
Fig. S4: Alterations in MYC/mTOR signaling is associated with more aggressive 
disease. A. Oncoprint showing the percent of patients with altered genetic and mRNA/
protein expression of MYC, mTOR, CIP2A, and SET (amplification, gain, expression 
>2, protein >2), as well as PPP2CA (homozygous deletion, heterozygous loss, 
expression <-1, protein <-1, mutation). B. Overall survival of the patients analyzed in 
panel A. p=0.04 Mantel-Cox test  
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Supplemental Figure 5 
Fig. S5:  Phosphorylation at T58A in response to DT1154 and INK128 treatment. 
PANC89 and PANC1 cells were treated with Vehicle, DT1154 (10µM), INK128 (0.5µM), 
or the combination for 6 hours and then harvested for western blot analysis. Lysates 






























































Supplemental Figure 6 
Fig. S6: Increased MYC expression alters the efficacy of INK128. A. PANC89 cells were treated 
with a non-targeting siRNA or siRNA to PPP2R5A (B56a). Cells were harvested 48 hours after 
the addition of siRNA and B56a mRNA levels relative to siNT were assessed by qPCR. **p<0.01 
by two-tailed students t-test. B. Cells from panel A were treated with either Vehicle or 0.5µM 
INK128 for 6 hours. Lysates were analyzed by western blot for MYC, pAKT (S473), pS6 
(S235/6) and totals. Representative blots from three biological replicates are shown. C. Cells 
from panel A were treated with increasing concentrations of DT1154. Viability was assessed by 
MTS after 72 hours. Average +/-SD. Representative of three biological replicates shown. D. 
PANC89 cells transfected with AdGFP (GFP) or AdMYCT58A (T58A) were treated with either 
Vehicle or 0.5µM INK128 for 6 hours. Lysates were analyzed by western blot as above. 





















Supplemental Figure 7 
Fig. S7: Decreased expression of MYC increases the efficacy of INK128. A. PANC1 cells 
treated with non-targeting siRNA (siNT) or MYC targeting siRNA (siMYC) were treated 
with either Vehicle or 0.5µM INK128 for 6 hours. Lysates were analyzed by western blot 
for MYC, pAKT (S473), pS6 (S235/6) and totals. Representative blots from three biological 
replicates are shown. B. KPC or KPC Mfl/+ were treated with either Vehicle or 0.5µM 
INK128 for 6 hours. Lysates were analyzed by western blot as above. Representative 
blots from three biological replicates are shown. 
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Supplemental Figure 8 
Fig. S8: Decreased expression of Myc increases the efficacy of mTOR inhibitors. KPC and 
KPC Mfl/+ cells were treated with Vehicle or increasing concentrations of A. BEZ235, B. 
Dasastinib, or C. Sunitinib. Viability was assessed by MTS after 72 hours. Shown is the 
average +/-SD of two biological replicates.  
9	































































































































Supplemental Figure 9 
Fig. S9: DT1154 and INK128 reduce tumor growth in vivo. PANC89 cells were subcutaneously 
injected and treated with Vehicle, DT1154 (15 mg/kg), INK128 (0.5 mg/kg), or the combination. A. 
PANC89 xenograft tumors were treated until endpoint (long-term treatment). Representative H/E 
images at 2.5x (scale bar = 1mm) and 10x (scale bar = 200 mm) magnification for each drug 
treatment arm. *denotes necrotic areas. B. Tumors were grown as above and treated with Vehicle, 
DT1154 (15 mg/kg), INK128 (0.5 mg/kg), or the combination for 7 days. Tumor growth was 
measured over time. ***p<0.001 *p<0.05 by a 2-way ANOVA. C. Endpoint tumor weight from 
tumors harvested in panel B. *p<0.05 by a 1-way ANOVA. D. Necrotic areas identified from H/E 
tumor sections from panel B were quantified using ImageJ *p<0.05 by a two-tailed students t-test. 
E. Representative images from tumor sections from panel B stained with ApopTag Plus 
Peroxidase In Situ Kit. TUNEL staining shown on left, ImageJ mask of TUNEL positive cells on 
right. Scale bar = 100 mm. 
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Supplemental Methods:  
Fraction Affected Viability Curves, Cytotoxicity Assays, and Flow Cytometery 
For cytotoxicity assays, cells were plated in viability assays and prior to the addition of drug, 
CellTox Green (VWR) was added at a 1:2000 concentration. Cells were imaged on the IncuCyte 
ZOOM Live Cell Imaging System (Essen Bioscience) for 3 days. Live cell images were taken 
every 2 hrs and percent phase object confluence was calculated using IncuCyte Zoom software. 
The average green object count (1/mm2) across four pictures per well were quantified over time 
using the IncuCyte ZOOM software and the area under the curve was generated for each dose 
using Prism (GraphPad Software). For CalcuSyn fraction affected curves, cells were plated and 
treated for viability assays and then the fraction of cells affected (experimental – blank/Vehicle – 
blank) was plotted for each dose using CalcuSyn software (CalcuSyn). For detection of apoptotic 
cells by flow cytometery, PDA cell lines were plated into DMEM+2% FBS and then treated for 
48 hours with Vehicle, OP449, INK128, or the combination of OP449 and INK128. Cells were 
trypsinized, resuspended in PBS with 1% bovine serum albumin, and stained with Annexin V 
(BD Biosciences) as previously described (1).  
 
Immunoprecipitation 
Pancreatic cancer cells were plated in DMEM with 2% FBS and 24 hours later treated with either 
Vehicle, 10 M DT1154, 0.5  M INK128, or the combination of DT1154 and INK128 for 6 
hours. Cell lysates were sonicated for 10 pulses at 3 output and 20% duty and then incubated on 
ice for 15 minutes. Lysates were pre-cleared with 30 µl of 50% Protein A bead slurry (Repligen) 
for 1 hr at 4°C and then incubated with 2 µg of MYC or rabbit IgG antibody overnight at 4°C 
(SC-764, Santa Cruz Biotechnology). Samples were incubated with 30 µl of Protein A beads for 
1.5 hrs at 4°C and then washed 3 times and run on an SDS page gel. 
 
Soft Agar Assay 
For soft agar assays, 1.4% noble agar was mixed 1:1 with 2X DMEM with 4% FBS and plated in 
12 well plates. Cells were harvested and 40,000 cells were resuspended in 2X DMEM with 4% 
FBS. The cell suspension was then mixed 1:1 with 0.7% noble agar and plated on top of the base 
agar layer. Plates were fed twice a week with DMEM medium containing 2% FBS and either 
Vehicle or the indicated doses of DT1154, INK128, or combination. Plates were stained with 0.5 
ml 0.005% crystal violet over night at 4oC and the total number of colonies was counted in 
triplicate wells using ImageJ.  
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Kinase Inhibitor Screen 
Kinase inhibitor plates were purchased from the Oregon Translational Research and Development 
Institute and described previously (2). Briefly, pancreatic cancer cell lines were resuspended in 
DMEM+2%FBS media containing either Vehicle or OP449 (IC25 dose) and plated into 384-well 
kinase inhibitor plates at 1000 cells per well using the EP Motion (Eppendorf) automated 
pipettor. Inhibitor plates contained 7-point dilutions of 119 inhibitors with DMSO (Sigma) as a 
control. Plates were incubated for 72hr at 37°C in a 5% CO2 atmosphere and viability was 
measured using CellTiter 96 cell viability kit (Promega). IC50s of each drug relative to DMSO or 
DMSO+OP449 were calculated as previously described (2). The lowest IC50 for each compound 
across technical and biological replicates was then used to calculate the relative fold change in 
IC50 with the addition of OP449. Full list of kinase inhibitors and IC50s are listed in 
Supplemental Table 1.  
 
Survival Curves and Oncoprint 
Oncoprint and overall survival of mutant KRAS patients in the TCGA Pancreatic 
Adenocarcinoma Provisional dataset was generated using cBioPortal (3, 4). The dataset was 
queried for amplification, gain, and increased mRNA/protein expression (2>) of MYC, mTOR, 
CIP2A, and SET, and homozygous loss, heterozygous deletion, mutation, and decreased 
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